Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: real-world data from the PROSE registry

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• PROSE is an ongoing, observational registry in the USA and Canada enrolling real-world patients receiving dupilumab treatment for atopic dermatitis; as of July 2019, 315 patients were enrolled.
• At baseline, mean EASI (eczema area and severity index) was 16.9, which decreased to 4.4 by Month 6.
• Baseline mean Patient-Oriented Eczema Measure (POEM) was 18.5, decreased to 6.9 by Month 6; similar improvements were also seen in itch and quality of life.
• This real-world study demonstrates improvement over the initial 6 months of dupilumab treatment using both investigator-assessed and patient-reported outcomes.